Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia

Medicine & Life Sciences

• Esterification 87%
• Imatinib Mesylate 76%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 70%
• avasimibe 66%
• Cholesterol 49%
• Cholesterol Esters 40%
• Mutation 37%
• Growth 33%
• Phosphotransferases 25%
• sterol O-acyltransferase 1 20%
• Protein-Tyrosine Kinases 20%
• 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 16%
• Dasatinib 15%
• Cell Proliferation 14%
• K562 Cells 13%
• Therapeutics 10%
• Heterografts 10%
• Leukemia 9%
• Down-Regulation 7%
• Cell Line 6%
• Neoplasms 3%

Agriculture & Biology

• esterification 72%
• leukemia 71%
• cholesterol 51%
• mutation 45%
• phosphotransferases (kinases) 40%
• cholesteryl esters 33%
• cells 21%
• cell proliferation 17%
• cholesterol acyltransferase 14%
• prognosis 11%
• animal models 8%
• therapeutics 7%
• neoplasms 7%
• cell lines 7%

Chemical Compounds

• Imatinib 100%
• Esterification 60%
• Cholesterol 59%
• Cholesteryl Ester 44%
• Mutation 37%
• Tyrosine Kinase Inhibitor 31%
• Resistance 28%
• Nilotinib 19%
• Acyl-CoA 14%
• Cytometry 11%